GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation
Will Assess Its HERVs MAb Temelimab in Covid-19 Patients
Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.
